OpenAI is in talks with the FDA to leverage AI in drug evaluation processes, discussing methods to enhance efficiency and accuracy in medical assessments. This initiative aims to streamline data analysis and patient outcomes in the U.S., potentially revolutionizing regulatory practices in pharmaceutical sectors.
🤖 OpenAI Collaborates with FDA on AI Drug Evaluations
